Information  X 
Enter a valid email address

Clinigen reiterates guidance for 2021 revenue as virus impact continues

By BFN News | 10:04 AM | Thursday 26 November, 2020

Pharmaceutical company Clinigen reiterated its outlook for 2021 organic net revenue growth to be toward the lower end of its 5%-to-10% medium-term guidance range. The company said trading in 2021 had been in-line with market expectations despite the ongoing impact of COVID-19. 'As previously stated, we expect growth to be more weighted to H2 than in previous years due to the impact of COVID-19 and the timing of shipments for Proleukin to key customers,' the company said. At 10:04am: (LON:CLIN) Clinigen Group PLC share price was 0p at 683p Story provided by

a d v e r t i s e m e n t